| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 30381 | Journal of Photochemistry and Photobiology B: Biology | 2014 | 10 Pages |
•Combination therapy of chemotherapy and photodynamic therapy was evaluated.•Hypocrellin A and 7-ethyl-10-hydroxycamptothecin were co-loaded on graphene oxide.•The complex was formed through noncovalent π–π stacking and hydrogen bond.•Combination therapy exhibited a synergistic anticancer effect to cancer cell.
Previous research indicated that graphene oxide (GO) can be used to deliver photosensitive anticancer drug, Hypocrellin A (HA), in photodynamic therapy (PDT). However, the anticancer activity of HA was obviously decreased after been loaded on GO. To solve this problem, a chemotherapy drug, 7-ethyl-10-hydroxycamptothecin (SN-38), was co-loaded on the HA loaded GO (HA/SN-38/GO) as a multimodal carrier for the synergistic combination of PDT and chemotherapy for cancer. In vitro results showed that the combination therapy exhibited a synergistic antiproliferative effect compared with PDT and chemotherapy alone. Therefore, HA/SN-38/GO delivery system has the potential to offer dual therapies for the synergistic combination of PDT and chemotherapy for the treatment of cancer.
Graphical abstractGraphene oxide was exploited as a multimodal carrier of photosensitizers and chemotherapeutics for the synergistic combination therapy to cancer.Figure optionsDownload full-size imageDownload as PowerPoint slide
